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Human GIP l-42 and fragments of human GIP corresponding to GIP 10-42, GIP 1 l-42, and GIP 17-42 
were isolated from acid-ethanol extracts of human small intestines with the aid of an anti-GIP serum 
specific for the extreme C-terminal portion of the GIP molecule. The full sequence of human GIP has been 
established by Edman degradation of these peptides and fragments thereof by automatic gas-phase 
sequencing. Human GIP differs from porcine GIP at residues 18 and 34. The sequence of human GIP 
is thus: Tyr-Ala-Glu-Gly-Thr-Phe-Ile-Ser-Asp-Tyr-Ser-Ile-Ala-Met-Asp-Lys-Ile-His-Gln-Gln-Asp-Phe- 
5 10 15 20 
Val-Asn-Trp-Leu-Leu-Ala-Glu-Lys-Gly-Lys-Lys-Asn-Asp-Trp,Lys-His-Asn-Ile-Thr-Gln. Amino acid 
25 30 35 40 
residues 18 and 34 are Arg and Ser, respectively, in porcine GIP. 
Human Gastric inhibitory peptide 
1. INTRODUCTION 
The intestinal peptide gastric inhibitory peptide 
(GIP) was first isolated from porcine upper small 
intestine on the basis of its ability to inhibit 
histamine-stimulated gastric acid secretion in the 
dog Heidenhan pouch [l]. Porcine GIP contains 
42 amino acid residues [2,3]. The peptide is a po- 
tent releaser of insulin in experimental animals [4] 
and in man [5,6] provided that the blood glucose 
is above basal levels. Plasma levels of im- 
munoreactive GIP (IRGIP) are elevated after an 
oral glucose load or a meal in normal man. This in- 
crease after a meal is below normal in newly 
diagnosed insulin-dependent diabetics [7]. GIP, 
therefore, could be of use as a glucose-dependent 
insulin-releasing peptide in at least some diabetics. 
The isolation and sequencing of human GIP were 
undertaken to ensure that the optimal peptide 
could be available in the event of GIP being of 
diagnostic or therapeutic use in man. We report 
Intestine Isolation Sequence 
here the isolation and sequencing of human GIP 
from post-mortem human small intestines. 
2. MATERIALS AND METHODS 
2.1. Isolation of GIP 
Human small intestines were obtained post 
mortem, rinsed and rapidly frozen in contact with 
solid COZ. The intestines were kept frozen at 
- 20°C until extracted. Two intestines (A,B) were 
extracted separately. The intestines were collected 
12 and 6 h post mortem, respectively. 
The deep-frozen intestines were broken into 
small pieces with a hammer while at - 20°C and 
homogenized while frozen in 4 vols (w/v) of 0.3% 
phoshoric acid in 80% (v/v) ethanol. After 
homogenization the extracts were stirred for 
30 min at 4°C. The tissue was collected by cen- 
trifugation and reextracted in 4 vols (w/v) of 0.3% 
phosphoric acid in 65% (v/v) ethanol. The super- 
natants from the two extractions were pooled. 
142 
Publrshed by Elsewer Science Publrshers B. V. 
00145793/84/$3.00 0 1984 Federation of European Biochemical Societies 
Volume 172, number 2 FEBSLETTERS July 1984 
Peptides were defatted and precipitated by ad- 
ding 4 vols (v/v) acetone to the ethanolic extracts 
and by centrifuging after 30 min stirring at room 
temperature. The crude peptide precipitates were 
dissolved in 10% acetic acid and clarified by cen- 
trifugation at 10000 x g for 30 min followed by 
filtration through a 0.45~pm Millipore fiiter. The 
peptides in the dissolved acetone precipitates were 
separated by reverse-phase and ion-exchange 
HPLC on a Spectra Physics SP 8700 solvent 
delivery system fitted with a Knauer Spec- 
tralphotometer 87~ and a Spectra Physics 
SP 4100 computing integrator. 
The distribution of IRGIP during purification 
was followed by a radioimmunoassay using the 
anti-GIP rabbit serum R65, standards of highly 
purified porcine GIP [3] and 1251-labelled porcine 
GIP. Standards (O-727 pM) or unknowns were in- 
cubated with ‘251-labelled GIP plus R65 (final dilu- 
tion 1: 8250) for 24 h and the free 1251-Iabeiled GIP 
separated from antibody-bound ‘*?-labelled GIP 
with ethanol [8]. The supernatants containing the 
free 125 I-labelled GIP were counted. The sensitivity 
of the assay was 3 pM standard (0.3 fmol/tube). 
The anti-GIP serum R65 reacts with the extreme C- 
terminus of porcine GIP [3], and does not react 
with gut peptides other than GIP [8]. 
2-2. Sequence analyses 
Edman degradation of peptides was performed 
with an Applied Biosystems model 470A gas-phase 
sequencer as in [9,10] with several modifications. 
A fourth solvent (Sl = n-heptane) was included for 
washing the filter for 30 s after coupling with 
PITC. To obtain the methylated erivatives of Asp 
and Glu, the conversion of amino acid 
aniiinothiazolinones to phenyfthiohydantoins 
(PTH-a.a.) was carried out with 1 N methanolic 
HCl (R4) instead of 25% trifluoroacetic acid. The 
sequencer program was adjusted to this reagent as 
shorter drying times were necessary. The PTH-a.a, 
were dissolved in approx. 0.25 ml methanol and 
dried in a Savant vacuum centrifuge for IO min at 
45°C. Dried PTH-a.a. were redissolved in 25 ~1 
methanol containing MTH-tyrosine as internal 
standard. The PTH-a.a. were identified and quan- 
tified by reverse-phase HPLC on an IBM cyano 
column [l 11 in a Hewlett Packard liquid 
chromatograph model 1084B equipped with a 
variable UV-detector model 79875. Details of the 
procedure are described in the legend to fig. 1. The 
PTH-a.a. were measured at 263 nm whereas the 
dehydro derivatives of serine and threonine were 
detected at 3 14 nm. 
2.3. Prepara$ion of GIP fragments 
To obtain sufficient peptides for sequencing the 
C-terminal part of GIP the following GIP 
fragments isolated from intestine B and identified 
by partial sequencing were mixed: GIP 17-42 
(650 pmol), GIP lo-42 (200 pmol) and GIP 1 l-42 
(150 pmol). The peptides were dried and redis- 
solved in 0.1 ml of 50 mM ~-ethyimorpholine buf- 
fer (adjusted to pH 8.0 with acetic acid) containing 
65 pmol Armillaria mellea protease, and incubated 
for 16 h at 37°C. A. mellea protease, which 
specifically cleaves at the N-terminal side of lysine 
residues, was purified from A. metlea f13]. The A. 
mellea protease digest was fractionated by HPLC 
(fig.2). 
One nmol GIP was cleaved at the tryptophan 
residues by oxidation of tryptophan to oxin- 
dolyialanine and methionine to methionine sulfox- 
I I 
4 6 8 10 12 14 
Retention time (mist) 
Fig.1. HPLC separation of PTH amino acids on the 
IBM cyano analytical column (25 x 0.46 cm) equipped 
with a Permaphase ETH guard column (5 x 0.46 cm, 
DuPont). Solvent A was 16 mM sodium acetate (pH 5.6) 
and solvent B acetonitrile/methanol (9: I, v/v). The 
column was equilibrated with 15% B and eluted with a 
linear gradient of 15-51.4% B from 0 to 15.30 min. The 
sample consisted of 5 ~1 methanol containing 12.5 pmol 
of each of the PTH amino acids. The flow rate was 
1.5 ml/min and the oven temperature 45°C. The PTH 
amino acids were detected at 263 nm at 1.5 mAUFS 
(corresponding to attn.-2’ at the Hewlett Packard 
798508 LC terminal). Peak Y’ corresponds to MTH- 
tyrosine used as internal standard. The detection limit 
was 1.7 pmol, defined as 2-times the noise level. 
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Fig.2. HPLC separation of GIP fragments obtained by 
cleavage of a mixture of GIP 17-42 (650 pmol), GIP 
lo-42 (200 pmol), and GIP II-42 (150 pmol) with A. 
mellea protease. The digest was fractionated on a 5 pm 
Waters, Nova Pak C-18 column (15 x 0.39 cm) with a 
linear gradient as indicated. Solvent A, 0.1% 
trifluoroacetic acid in HzO; solvent B, 0.07% 
trifluoroacetic acid in 50% (v/v) acetonitrile. Flow rate 
1.5 ml/min. Peptides corresponding to major peaks 
(A-E) were sequenced. 
ide by treatment with dimethylsulfoxide in 
hydrochloric acid followed by cyanogen bromide 
cleavage in formic acid [ 121. The digest was frac- 
tionated by HPLC. 
3. RESULTS 
3.1. Isolation of GIP 
The dissolved clarified acetone precipitates were 
fractionated separately on a 22.4 x 250 mm col- 
umn of LiChrosorb 1ORP 18. The part of the ef- 
fluent containing IRGIP was concentrated in 
vacua and the peptides purified on a 4.6 x 250 mm 
column of Nucleosil 5 PC-18. 
The elution patterns of extracts A and B from 
the two reverse-phase columns were similar 
(fig,3,4A,B). The peptide with IRGIP from extract 
A was isolated by freeze-drying from the effluent 
of the second C-18 column (fig.3B) and partially 
sequenced. The IRGIP peptide was found to be in- 
tact GIP contaminated with another peptide. The 
corresponding fraction from extract B (pool 2, 
fig.4A) was therefore purified on a 7.5 x 75 mm 
column of Waters SP-SPW. The fraction which 
eluted at 39.46 min (fig.4C) contained IRGIP and 
was freeze-dried to remove acetonitrile and am- 
monium formate. 
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Fig.3. Isolation of partially purified GIP from human 
small intestine A. Panel A, 230 ml dissolved acetone 
precipitate were applied at 10 ml/min to a 22.4 x 
250 mm column of LiChrosorb 10 RP18 equilibrated 
with 5% (v/v) acetonitrile in 100 mM ammonium 
formate (pH 3.3). After application of the sample 
(absorbance trace not shown) the column was eluted 
with a gradient of 10-5007’0 acetonitrile in ammonium 
formate for 200 min. Fractions were collected every 
30 s. Panel B, the concentrated IRGIP-containing 
fractions from the previous column were applied in 
1.4 ml to a 4.6 x 250 mm column of Nucleosil 5 p C-18 
equilibrated at 2 ml/min with 10% (v/v) acetonitrile in 
100 mM ammonium formate (pH 3.3). The column was 
eluted with a gradient of acetonitrile in ammonium 
formate as indicated. Fractions corresponding to the 
absorbance peaks were collected. 
Extract B contained a considerable amount of 
IRGIP which eluted before the main peak of GIP 
l-42 on the first reverse-phase HPLC separation, 
i.e., in pool 1 (fig.4A). This material was frac- 
tionated on a column of Waters SP 5PW, as 
described for the isolation of GIP l-42 (fig.4). 
Two broad zones of IRGIP were recovered, which 
eluted later than GIP l-42. The fractions contain- 
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ing these zones were separately purified on a 
Waters 5 /Nova Pak C-18 column (not shown). 
The material containing IRGIP was pooled and 
freeze-dried to give a total of 1 .O nmol mixed GIP 
fragments. The total yield of IRGIP from the two 
extractions was approx. 4 nmol out of which about 
1 nmol were GIP fragments (table 1). 
3.2. Sequence analyses 
By sequencing the intact GIP from extract A the 
main part of the structure, 31 out of 42 residues, 
was elucidated (fig.5, table 2). During the sequence 
analysis of intact GIP a contaminating peptide 
with an N-terminal sequence of Met-Gln-Ile-Phe- 
Val- was identified. 
c- 
Fig.4. The isolation of GIP and GIP fragments from 
human small intestine B. Panel A, 400 ml dissolved 
acetone precipitate were applied at 10 ml/min to a 
22.4 x 250 mm column of LiChrosorb 10 RP18 
equilibrated with 5% (v/v) acetonitrile in 100 mM 
ammonium formate (pH 3.3, absorbance trace not 
shown). Other details as in fig.3A. Panel B, the 
concentrated IRGIP-containing fractions from the 
previous column were applied in 3 aliquots of 1.3 ml to 
a 4.6 mm x 250 column of Nucleosil 5,u C-18 
equilibrated at 2.0 ml/min in 10% (v/v) acetonitrile in 
100 mM ammonium formate (pH 3.3). The column was 
eluted with a gradient of acetonitrile in ammonium 
formate as indicated. Fractions corresponding to the 
absorbance peaks were collected. Panel C, the 
concentrated IRGIP-containing fractions from the 
previous column (shaded area, panel B) were applied in 
6 aliquots of 1.6 ml to a 7.5 x 75 mm column of Waters 
SP-5PW equilibrated with 50 mM ammonium formate 
(pH 5.0) in 20% (v/v) acetonitrile at 1.2 ml/min. The 
column was eluted with a gradient of ammonium 
formate (pH 5.0) in 20% (v/v) acetonitrile as indicated. 
Fractions corresponding to the absorbance peaks were 
collected. 
By use of Dayhoff’s Protein Segment Dictionary 
[14] the contaminating peptide was identified as 
human ubiquitin. This peptide was present in 
15-20070 of the amount of GIP. Since the sequence 
of human ubiquitin is known [15] this contamina- 
tion did not cause any serious trouble in the 
elucidation of the GIP sequence; in fact, the se- 
quence of human ubiquitin 1-26 was confirmed. 
However, the presence of ubiquitin in the GIP 
preparation was the main reason that the GIP se- 
quence could not be read beyond residue 31. 
The strategy for the sequencing of the C- 
terminal part was based on the following observa- 
tions: (i) the-human GIP sequence 1-31 showed a 
strong homology with porcine GIP which meant 
that a tryptophan residue (with high molar absorp- 
tion at 230 nm) could be expected in the C- 
terminal part; (ii) model experiments with porcine 
GIP digested with the N-terminal lysine-specific A. 
mellea protease showed that porcine GIP 37-42 
could be detected with antibody R65; (iii) the 
model experiments with porcine GIP showed that 
the digestion with A. mellea protease could be car- 
ried out specifically and in high yields, and that 
peptide retention times in the HPLC system used 
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Table 1 
Recovery of IRGIP from extracts of human small intestine 
(I) Extract A (841 g small intestine) 
Stage Volume 
(ml) 
GIP 
(nmol/l) 
Total GIP 
(nmol) 
Yield 
(To) 
Acid-ethanol extract 2700 6.4 17.3 100 
Dissolved acetone precipitate 230 78.6 18.1 105 
Large-scale HPLC, pool 1 12 566 6.8 39 
Small-scale HPLC, fraction R, 50.39 min 3 0.9 2.7 16 
(II) Extract B (610 g small intestine) 
Stage Volume 
(ml) 
IRGIP Total IRGIP Recovery 
(nmol/l) (nmol) (Q) 
Extract 
Dissolved acetone precipitate 
Large-scale HPLC 
Pool 1 (GIP fragments) 
Pool 2 (intact GIP) 
Small-scale HPLC (pool 2) 
Fraction R, 36.10 
SP HPLC 
Fraction R, 39.46 
3600 6.3 21.9 100 
400 29 11.6 53 
35 94 3.3 
25 176 4.4 35 
3 750 2.2 10 
3 333 1.0 4.5 
(fig.2) could be predicted rather accurately from from extract B (pool 1, fig.4B) was fractionated by 
the peptide amino acid composition as in [16]. HPLC (fig.2), and peptides isolated from pools 
The A. mellea protease digest of the mixture of A-E were sequenced. Fragments A and B 
human GIP 17-42, GIP 10-42, and GIP 11-42 represented the GIP sequences 33-36 and 37-42, 
5 10 15 20 
Tyr-Ala-Glu-Gly-Thr-Phe-lle-Ser- Asp-Tyr-Ser-lle-Ala-Met-Asp-Lys- Ile-His-Gln-Gln-Asp- 
-_)---_,~~-_)_)_)---,-_)~_)-~‘-_)~---_)-_)’--_, 
25 30 35 40 
Phe-Val-Asn- Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys- Lys-Asn-Asp-Trp , Lys-His-Asn-lle- Thr-Gln 
---c~---_) +--w---L-_,_,~ ---lr 
-- -L-----L- 
I I 
AMP-A 
I 
AMP-B 
I 
7-r-------c-Y 
I 
W-l 
I 
Fig.5. Amino acid sequence of human GIP. The sequence was deduced from the Edman degradation of intact GIP (-) 
(table 2), A. meflea protease-fragment A (AMP-A) and B (AMP-B) (-), and fragment W-l (-) (table 3). 
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Table 2 
Sequence analysis of intact human GIP 
Cyclus 
ll0. 
6 6 Phe 10.59 
7 7 Be 772 
8 8 Ser 142 
9 9 Asp 385 
10 10 TYr 625 
I1 11 Ser 93 
12 12 Be 318 
13 13 Ala 517 
14 14 Met 439 
15 15 Asp 227 
16 16 Lys 294 
17 17 Be 226 
18 18 His 57 
19 19 Gin 145 
20 20 Cln 116 
21 21 Asp 137 
22 22 Phe 171 
23 23 Val 172 
24 24 Asn 144 
25 25 Trp 70 
26 26 
27 27 
28 28 
29 29 
30 30 
31 31 
32 32 
33 33 
34 34 
35 35 
Residue 
IlO. 
PTH-a.a. Yield 
(pmol) 
TY~ 1768 
Ala 1362 
GIU 981 
GJY 934 
Thr 491 
Leu 
Leu 
Ala 
Gin 
LYS 
GJY 
189 
260 
138 
63 
95 
64 
Asp 77 
Amount applied, 2000 pmol; initial yield, 88.4%; 
average repetitive yield, 89.2% 
respectively (table 3). By peptide sequencing with 
the gas-phase sequencer the ‘carryover’ from step 
N-l is usually 5-S% (unpublished). However, the 
carryover observed by sequencing fragment A was 
approx. 25%, and a minor part of the peptide 
material isolated from pool A (fig.2) could have 
been the peptide of Lys-Lys-Asn-Asp-Trp (GIP 
32-36) resulting from incomplete cleavage bet- 
ween Lys 32 and Lys 33. Fragments D and E 
represented the GIP sequences 16-29 and 17-29, 
respectively (not shown). Fragment C contained 
the sequence of Lys-Asn-Asp-X, This sequence 
probably represents a peptide with a derived form 
of tryptophan in position X. 
To confirm the structure around residue 32, in- 
tact GIP from extract B was cleaved at the tryp- 
tophan residues, and the digest was fractionated by 
HPLC as described in the legend to fig.2. A pep- 
tide fragment (W-l) eluting with a retention time 
of 19.76 min was isolated and sequenced. 
Although the yield from the tryptophan cleavage 
was only 80 pmol (about 8%), 10 out of 11 
residues could be identified, thus confirming the 
sequence from position 26 to 35 (table 3). 
Based on the above sequence analyses, the 
primary structure of human GIP could be deduced 
(fig.5). Due to the small amount of human GIP 
available, the peptide bond between Trp 36 and 
Lys 37 has not been confirmed by peptide sequenc- 
ing, and no total amino acid analysis has been car- 
ried out to support the sequence. However, con- 
sidering the fragmentation procedures used and 
the strong homology of human GIP to porcine 
GIP (40 out of 42 residues are identical) the 
presence of ‘extra’ amino acid residues between 
position 36 and 37 seems rather unlikely although 
not theoretically impossible. 
4. DISCUSSION 
In view of the difficulty in obtaining fresh 
human intestine, our work was carried out with 
post-mortem tissue. The nature of the starting 
material was probabfy responsible for the small 
amount of IRGIP extracted from the tissue and for 
the heterogeneity of this IRGIP. This heterogenei- 
ty of the IRGIP led to the isolation and sequencing 
of several ‘natural’ GIP fragments. Despite the 
small amounts of IRGIP present in the starting 
materia1 (approx. 20 nmol/intestine) and its 
heterogeneity, the full sequence of human GIP has 
been deduced. 
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Sequence analysis of GIP fragments 
Fragment Cyclus no. Amount Initial 
applied yield 
1 2 3 4 5 6 7 8 9 10 11 (pmol) (070) 
A. mellea protease 
fragment A 
Yield (pmol) 
A. mellea protease 
fragment B 
Yield (pmol) 
W-l 
Yield (pmol) 
Lys- Asn-Asp-Trp 
285 168 124 28 
Lys- His- Asn-Ile- Thr- Gln 
47 26 67 59 15 5 
Leu- Leu- Ala- Gln- Lys- Gly- Lys- Lys- Asn-Asp- 
36 33 26 13 6 18 4 5 12 3 
800 36 
80 59 
80 45 
The full sequence of human GIP differs from 
that of porcine GIP in that Arg 18 is replaced by 
His 18 and Ser 34 by an Asn 34. Both of these 
changes might represent a single base change at the 
DNA level. The effect of these changes on the 
biological activity of human GIP compared to por- 
cine GIP cannot be predicted. It can, however, be 
concluded that these changes can account for the 
different reactivity of human GIP in plasma with 
different anti-porcine GIP sera [17] and the slight 
differences observed between porcine and human 
IRGIP on reverse-phase HPLC [18]. 
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